

**Haig Armen Goenjian, M.D.**  
Collaborative Neuroscience Network, LLC  
12772 Valley View Street, Suite 3  
Garden Grove, CA 92845

**CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, Alliance Director  
Tel. (916) 939-6696  
Fax (208) 575-3169  
Email: clinicaltrials@alliancesites.com

**AFFILIATIONS:**

Collaborative Neuroscience Network, LLC  
19401 S. Vermont Avenue, Suite F-100  
Torrance, CA 90502

Collaborative Neuroscience Network, LLC  
2600 Redondo Avenue, Suites 415 & 500  
Long Beach, CA 90806

Ocean View Psychiatric Health Facility  
2600 Redondo Avenue, Suite 500  
Long Beach, CA 90806

**EDUCATION:**

2007 - 2011 Doctor of Medicine  
Tulane University School of Medicine, New Orleans, LA

2006 - 2007 Anatomy Certification Program  
Tulane University School of Medicine, New Orleans, LA

2001 - 2005 B.A. in Philosophy  
UCLA, Los Angeles, CA

**RESIDENCY:**

2015 - 2016 Chief Residency  
UCLA Harbor Medical Center, Los Angeles, CA

2012 - 2016 General Psychiatry Residency  
UCLA Harbor Medical Center, Los Angeles, CA

**INTERNSHIP:**

2011 -2012 Preliminary Surgical Internship  
UCLA Harbor Medical Center, Los Angeles, CA

**CERTIFICATION:**

Board Certified Psychiatry 2016  
ACLS - 2011 - 2013  
BCLS - 2011 - 2016

**LICENSURE:**

Licensed Physician and Surgeon, State of California, License No. 123098

**PROFESSIONAL EXPERIENCE:**

*Investigator*, 2018 - Present  
Collaborative Neuroscience Network, LLC

*Sub-Investigator*, 2016 - Present  
Collaborative Neuroscience Network, LLC

*Research Coordinator*, 2008 - 2011  
Tulane University School of Medicine, New Orleans, LA

*Volunteer Clinician*, 2008 - 2009  
Bridgehouse Tuberculosis Clinic, New Orleans, LA

*Primary Care Provider*, 2008 - 2009  
St. Anne's Mobile Tuberculosis Clinic, New Orleans, LA

*Research Assistant*, 2008  
UCLA David Geffen School of Medicine, Los Angeles, CA

*Teaching Assistant - Anatomy and Neuroscience*, 2007 - 2008  
Tulane University School of Medicine, New Orleans, LA

*Volunteer*, 2007  
Habitat for Humanity, New Orleans, LA

*Research Assistant/ Manager*, 2005 - 2006  
Collaborative Neuroscience Network, LLC, Garden Grove, CA

**RESEARCH EXPERIENCE:**

Phase I • ADHD • Binge Eating Disorder • Bipolar Disorder • Depression • Driving Simulation  
Healthy • Obsessive Compulsive Disorder • Schizophrenia and Schizoaffective Disorders •  
Sexual Dysfunction

**TRIAL EXPERIENCE:**

***Phase I Depression***

A Phase I Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Single Doses of XXX in Healthy Volunteers and Subjects with Treatment-Resistant Depression

A Phase I, Double-blind, Placebo-controlled, Single- and Multiple-Dose Study of XXX in Adult Participants with Major Depressive Disorder

A Phase I, Randomized, Double-blind, Controlled, 6-week Pilot Trial to Assess the Impact of Novel Digital Interventions Designed to Improve Cognitive Dysfunction as Adjunct Therapy to Antidepressant Medication in Adults with Major Depressive Disorder (MDD)

***Phase I Driving Simulation***

A Phase I, Driving Simulation Cross-Over Study of Sedative Effects of XXX Compared to XXX and Placebo

***Phase I Healthy***

A Phase I Double-blind, Placebo-controlled Crossover Study of XXX Using Ketamine Challenge, to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response Using PET Imaging in Healthy Subjects

A Phase I, Double-blind, Placebo-controlled, Crossover Study of XXX Using a Ketamine Challenge to Evaluate the Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

A Phase I, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 5-Period, Crossover Study Assessing the Effects of XXX Compared to XXX, XXX and Placebo on Simulated Driving Performance in Normal Healthy Participants

A Phase I, Open-Label, Randomized, 2-Way Crossover, Pilot Trial to Assess the Bioequivalence of Oral Doses of XXX versus XXX Tablets in Healthy Subjects

A Phase I, Double-Blind, Placebo-Controlled, Randomized, 2 Stage, 2 Way Crossover Study of a Single Oral Dose of XXX in Healthy Adult Subjects

**TRIAL EXPERIENCE (continued):**

A Phase I Open-Label, One-Sequence Study to Evaluate the Steady-State Comparative Bioavailability of Injectable and Oral INVESTIGATIVE DRUG

*Phase I Schizophrenia and Schizoaffective Disorders*

A Phase I, Open Label, Parallel-Design, Single Dose Study to Assess the Relative Bioavailability of XXX Extended-Release Suspension for Subcutaneous Administration XXX, in Vials compared to Prefilled Syringes, in Patients with Schizophrenia or Schizoaffective Disorder

A Phase I Randomized, Open-Label, Pilot Parallel Study To Determine The Relative Pharmacokinetic Characteristics Between XXX Versus Injectable Paliperidone Palmitate Following Different Dosing Regimens In Schizophrenia Alone Or As Use In Schizoaffective Disorders As An Adjunctive Therapy To Antidepressants

A Phase I Multicentre, Randomized, Open label, Steady state, Balanced, Two treatment, Two Period, Two-way Crossover, Bioequivalence Study Comparing XXX 6 mg capsule to the reference listed drug XXX capsule in patients with Bipolar I Disorder or Schizophrenia who are tolerating a stable dosing regimen of XXX 6 mg capsule once daily

A Phase I, 2-Part, Open-Label, Randomized, Crossover Pilot Trial to Assess the Relative Bioavailability of XXX versus XXX Oral Tablets in Subjects With Schizophrenia or Bipolar Disorder and 25-mg Oral Tablets in Healthy Subjects

A Phase I, Study to Evaluate the Effects of XXX on the Pharmacokinetic of XXX, in patients with Stable Schizophrenia

A Phase I Study to Evaluate the Effects of XXX-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of XXX in Patients with Stable Schizophrenia

A Phase I XXX Randomized, Double-blind, Crossover Study to Explore Dopamine Synthesis Capacity in the Whole Striatum after 2 weeks of Treatment with 150MG of XXX or Placebo in patients with Schizophrenia

A Pilot, Phase I, Randomized, Open Label, Parallel Group Study Assessing the Bioavailability of XXX vs. XXX in Adult Subjects with Schizophrenia and Schizoaffective Disorder

A Phase I Randomized, Double-blind, Positive and Placebo-controlled, Four-Arm Crossover Study of the Effects of XXX at Therapeutic and Supra-therapeutic Doses, on the QTc Intervals in Schizophrenic Patients

A Phase I Investigational Study to Evaluate Adherence of XXX in Adults with Schizophrenia

**TRIAL EXPERIENCE (continued):**

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study with Long-Acting Injectable (LAI) XXX Formulation to Evaluate Safety, Tolerability, and Pharmacokinetics of XXX in Subjects with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

A Phase Ib, Pivotal, Multiple-Dose, Pharmacokinetic Bioequivalence Trial Comparing Generic to Reference XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) in Patients with Schizophrenia or Schizoaffective Disorder

A Phase I, XXX Device Performance Study

A Phase I, Randomized, Crossover, Open-Label, Multiple Dose, Pivotal Pharmacokinetic Bioequivalence Study Comparing XXX Extended-Release IM 156 mg/1 mL (100 mg eq) with XXX in Subjects with Schizophrenia or Schizoaffective Disorder

A Phase I Study to Evaluate the Effect of Multiple Doses of XXX on QTc Interval in Subjects with Schizophrenia

A Phase I Evaluation of the Effect of XXX on Cariprazine Exposure in Patients with Schizophrenia

A Phase I, Two-part, Open-label, Randomized, Exploratory and Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of XXX Long-acting Injectable Administered Subcutaneously or Intramuscularly in Adult Subjects with Schizophrenia

A Phase I Randomized, Open-Label, Parallel Design, Multiple-Dose, Comparative Bioequivalence Study of XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) Versus XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) in Schizophrenia Patients Already Stabilized on XXX

A Phase I, Study to Evaluate the Effects of XXX on the Pharmacokinetic of XXX, in patients with Stable Schizophrenia

A Phase I Study to Evaluate the Effects of XXX-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of XXX in Patients with Stable Schizophrenia

A Phase I, Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Trial to Evaluate the Effects of XXX in Patients with Negative Symptoms of Schizophrenia of Schizophrenia treated with Antipsychotics

A Phase I, Pilot, 20-Week, Open-Label, Randomized, Single-Dose, Two-Treatment, Crossover Study of XXX Long-Acting Injection, 25 mg and XXX, 25 mg in Male and Female Schizophrenic Subjects

**TRIAL EXPERIENCE (continued):**

A Phase I, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXX in Subjects with Schizophrenia

***Phase II-IV***

***ADHD***

A Phase III, Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of XXX Sustained-Release Tablets in Adults with Attention-Deficit/ Hyperactivity Disorder

A Phase III, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety and Tolerability of XXX Sustained-release Tablets in Adults with Attention-deficit/ Hyperactivity Disorder

An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of XXX Sustained-Release Tablets in Adults with Attention-Deficit/ Hyperactivity Disorder

A Phase II Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of XXX in Adult Subjects (Ages 18-55) with Attention Deficit Hyperactivity Disorder (ADHD)

A Phase II, Multicenter, Randomized, Double-blind, Active and Placebo-controlled Trial of the Safety and Efficacy of XXX in the Treatment of Adult Attention deficit/Hyperactivity Disorder

***Bipolar Disorder***

A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of XXX for the Treatment of Subjects with Bipolar Disorder I/II with a Current Major Depressive Episode

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXX for the Treatment of Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression)

A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of XXX in the Treatment of Subjects with Bipolar I Disorder

A Multicenter, Randomized, Double-blind Trial of XXX versus Placebo for the Acute Treatment of Subjects Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

**TRIAL EXPERIENCE (*continued*):**

A Phase III, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter, Fixed Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of XXX in Patients with Bipolar I Depression

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXX Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

A Phase III, , Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXX Adjunctive to Lithium or Valproate in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

***Depression***

A Phase III, Multicenter, Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy of XXX in the Treatment of Adult Subjects with Major Depressive Disorder

A Phase III, Double-blind, Placebo-controlled Study of XXX as an Adjunct to Antidepressants in the Treatment of Patients with Major Depressive Disorder who have had an Inadequate Response to Antidepressants Alone

A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study of XXX in the Prevention of Relapse in Patients with Major Depressive Disorder

A Phase III, Final Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of XXX as Adjunctive Therapy in the Maintenance Treatment of Adults with Major Depressive Disorder

A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Trial to Assess the Safety and Tolerability of a 7-Day Dosing with XXX 25 mg QD and 50 mg QD as Adjunctive Therapy in the Treatment of Patients Diagnosed with Major Depressive Disorder

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of XXX as Monotherapy in Patients with Major Depressive Disorder

A Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of XXX as Adjunct to Current Antidepressant Therapy in Patients with Major Depressive Disorder (MDD) with an Inadequate Response to Current Antidepressants

A Phase IIb, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (5.0 mg or 2.5 mg) of XXX in Adult Patients with Major Depressive Disorder

**TRIAL EXPERIENCE (continued):**

A Phase IIIb, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of XXX in a Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients whose Current or Most Recent Episode is Manic, With or Without Mixed Features

A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of XXX for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder

A Phase III, Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal XXX in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidality, in Subjects Assessed to be at Imminent Risk for Suicide

A Phase II, 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of XXX versus XXX Extended-Release as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

A Study of XXX Plus XXX in Treatment-Resistant Depression (TRD)

A Phase II, Depression Diagnostic Aid Confirmatory Performance Study - An Abbreviated Investigational Device Exemption Study

A Phase II, Randomized, Double-blind, Placebo-Controlled, Parallel-groups Safety and Efficacy Study of XXX Administered Once Daily in Patients with Major Depressive Disorder with or without Anhedonia

A Phase II, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of XXX in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder

A Phase IIa, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of XXX as an Adjunctive Treatment for Patients with Major Depressive Disorder with an Inadequate Response to Current Antidepressant Treatment

A Phase II, Multicenter, Randomized, Double-blind, Placebo controlled, Study to Evaluate the Efficacy and Safety of Adjunctive XXX in Major Depressive Disorder

A Phase III, Multicenter Extension Study of XXX to Assess the Long-term Safety and Tolerability of XXX for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy



**TRIAL EXPERIENCE (continued):**

An Phase III, Open-label, Long-term Safety Study of XXX as Adjunctive Therapy in Patients with Major Depressive Disorder

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of XXX as Adjunctive Therapy in the Prevention of Relapse in Patients with Major Depressive Disorder

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of XXX as Adjunctive Therapy in Major Depressive Disorder

A Phase III, Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of XXX Administered Orally to Subjects with Treatment Resistant Major Depressive Disorder

A Phase II, Longitudinal Observational Cohort Study of XXX, a Neurogenic Compound among Out-Patients with Major Depressive Disorder

A Phase II, Double-Blind, Placebo-Controlled Study of XXX 40mg QD and 40mg BID among Outpatients with Major Depressive Disorder

A Phase III, Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal XXX Plus an Oral Antidepressant in Adult Subjects with Treatment-resistant Depression

A Phase III, Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal XXX Plus an Oral Antidepressant in Adult Subjects with Treatment-resistant Depression - Trial of Rapid-acting Intranasal XXX for Treatment-resistant Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled, Phase IV, Relapse Prevention Study Evaluating the Efficacy and Safety of XXX (5, 10 and 20 mg) in Adults With Major Depressive Disorder

A Phase III Multicenter Study of the Long-term Safety and Tolerability of XXX for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy

A Phase III Efficacy and Safety Study of XXX for the Adjunctive Treatment of Major Depressive Disorder

***Schizophrenia and Schizoaffective Disorders***

A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of XXX for the Treatment of Negative Symptoms of Schizophrenia

**TRIAL EXPERIENCE (*continued*):**

A Phase II, Randomized, Double-blind, Multiple-dose, Placebo-controlled Study to Evaluate the Safety and Efficacy of XXX in Subjects with Cognitive Impairment Associated with Schizophrenia (CAIS)

A Phase II Randomized, Sham-Controlled Study of XXX as an adjunct to standard-of-care treatment for schizophrenia

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of XXX in Patients with Negative Symptoms of Schizophrenia

A Phase II Study to Assess the Safety, Tolerability, and Efficacy of XXX in Hospitalized Adults with DSM-5 Schizophrenia

To create opportunities for the XXX Sponsor to interface with people with schizophrenia and to obtain their feedback on XXX prototypes

An open label, two-part study to evaluate the feasibility and engagement of using XXX in patients with schizophrenia

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of XXX as Add-on Treatment for Cognitive Impairment in Subjects with Schizophrenia on Stable Doses of Antipsychotic Medication

A Phase III, Multicenter, Multi-national, Double-blind (DB), Placebo-controlled, Randomized-Withdrawal Study Evaluating the Safety and Efficacy of XXX Compared with Placebo in the Prevention of Relapse in Patients with Schizophrenia

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension XXX for Subcutaneous Use as Maintenance Treatment in Adult Patients with Schizophrenia

A Phase III Study to Evaluate the Effect of XXX Compared to XXX on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness

A Phase II, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose levels of XXX in Adjunctive Treatment of Adult Subjects with Negative Symptoms of Schizophrenia

A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-Controlled, Monotherapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of XXX in Adult Patients with Negative Symptoms of Schizophrenia, Followed by 36-Week Open-Label Extension

**TRIAL EXPERIENCE (continued):**

A Phase IIIb, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of XXX or XXX for the treatment of schizophrenia in subjects hospitalized for acute exacerbation

A Double-blind, Randomized, Active-controlled, Parallel-group Study of XXX 6-Month Formulation

A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX During a 28-week Treatment Period as Adjunctive Therapy to Antipsychotic Treatment for the Prevention of Relapse in Patients with Schizophrenia

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of XXX in Patients with Acute Exacerbation of Schizophrenia

A Phase III, Study to Assess the Long-Term Safety, Tolerability, and Durability of Treatment Effect of XXX in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of XXX using XXX as an Active Control in Subjects Experiencing an Acute Episode of Schizophrenia

A Phase II, 26-Week Open-label Safety and Tolerability Extension Study of XXX in Adult Subjects with Schizophrenia

An Adaptive Phase II/III, Double-Blind, Randomized, Placebo- controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of XXX, a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy with XXX, for Residual Symptoms of Refractory Schizophrenia in Adults

An Adaptive Phase IIb/III, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of XXX, a D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adults

A Phase II, 4-Week, Randomized, Double-blind, Parallel-group, Placebo controlled, Flexibly-dosed, Multicenter Study to Evaluate the Efficacy and Safety of XXX in Acutely Psychotic Adult Subjects with Schizophrenia

A Phase III, Open-Label, Multi-Center Trial to Assess the Safety and Effectiveness of XXX in Patients with Schizophrenia

A Phase IIb, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of XXX as Adjunctive Treatment in Patients with Cognitive Impairment Associated with Schizophrenia Treated with Antipsychotics

**TRIAL EXPERIENCE (*continued*):**

A Phase II Randomised, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Once Daily Oral Doses of XXX over 12 week Treatment Period in Patients with Schizophrenia

An Interventional, open-label, flexible-dose, long-term safety study of XXX in adult patients with schizophrenia

Pilot study for Validation Test Plan XXX study

A Phase III, Multicenter Study to Assess the Long Term Safety and Tolerability of XXX in Subjects with Schizophrenia

XXX for Cannabis Use Disorder in Schizophrenia

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week Study to Assess Safety and Efficacy of XXX Transdermal Patch for the Treatment of Schizophrenia AND A Phase II/ III, Randomized, Double-Blind, Placebo-Controlled, 52-week Study to Assess Efficacy and Safety and Tolerability of XXX Transdermal Patch as Maintenance treatment in Adults with Schizophrenia

A Phase III, Interventional, Randomised, Double-blind, Active-controlled, Fixed-dose Study of XXX in Patients with Treatment-resistant Schizophrenia

A Phase III, One Year, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX as a Maintenance Treatment in Patients with Schizophrenia

A Phase III, Study to Evaluate Weight Gain of XXX Compared to XXX in Adults with Schizophrenia

A Phase III, Study to Determine the Antipsychotic Efficacy and Safety of XXX in Adult Subjects with Acute Exacerbation of Schizophrenia

A Phase III, Multicenter Study to Assess the Long Term Safety and Tolerability of XXX in Subjects with Schizophrenia

A Phase IV, Safety and Tolerability of Initiating XXX in Subjects with Schizophrenia who are Inadequately Treated with XXX

A Phase II, multicenter, randomized, double blind, placebo-controlled study to assess the efficacy, safety and tolerability of XXX for the treatment of negative symptoms of schizophrenia

**TRIAL EXPERIENCE (*continued*):**

A Phase III, Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment with XXX Long-Acting Injection or Oral Antipsychotics

A 12 week, Phase IIa Randomized, Double-blind, Placebo controlled, Parallel Group Study to Evaluate the Safety, Efficacy and Pharmacokinetics of XXX in Subjects with Cognitive Impairment Associated with Schizophrenia (CIAS)

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week Study to Assess Safety and Efficacy of XXX Transdermal Patch for the Treatment of Schizophrenia AND A Phase II/ III, Randomized, Double-Blind, Placebo-Controlled, 52-week Study to Assess Efficacy and Safety and Tolerability of XXX Transdermal Patch as Maintenance treatment in Adults with Schizophrenia

***Other Indications***

A Phase II/III Randomized, Double-blind, Placebo-controlled Trial of XXX in Subjects with Obsessive Compulsive Disorder

A Phase III, 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in Adults with Moderate to Severe Binge Eating Disorder

A Phase IV, Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Study Evaluating the Effect of XXX 10 and 20 mg/day vs XXX 20 mg/day on Sexual Functioning in Healthy Subjects

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Administered XXX in Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) (with or without Decreased Arousal)

**MEDICAL AWARDS:**

Excellence in Psychiatric Education Award - Southern California Psychiatric Society (2016)

Aron Academic Scholarship Award - Tulane School of Medicine Annual Scholarship based on Academic Performance (2007 - 2011)

Tulane School of Medicine Dean's Award for a Medical Student (2009)

Research Days Award: Annual Research Award at Tulane School of Medicine. First-Place Award achieved for the presentation, "Incidence of Primary Cleft Pathology in Greater New Orleans Pre- and Post-Katrina."

**PUBLICATIONS:**

Risk factors associated with psychiatric readmission.

Lorine K, Goenjian H, Kim S, Steinberg AM, Schmidt K, Goenjian AK.  
*J Nerv Ment Dis.* 2015 Jun;203(6):425-30.

Diagnostic accuracy of maxillofacial trauma two-dimensional and three-dimensional computed tomographic scans: comparison of oral surgeons, head and neck surgeons, plastic surgeons, and neuroradiologists.

Jarrah R, Vo V, Goenjian HA, Tabit CJ, Katchikian HV, Kumar A, Meals C, Bradley JP.  
*Plast Reconstr Surg.* 2011 Jun;127(6):2432-40. doi: 10.1097/PRS.0b013e318213a1fe.

Incidence of cleft pathology in Greater New Orleans before and after Hurricane Katrina.

Goenjian HA, Chiu ES, Alexander ME, St Hilaire H, Moses M.  
*Cleft Palate Craniofac J.* 2011 Nov;48(6):757-61. doi: 10.1597/09-246. Epub 2011 Feb 8.

PTSD and dopaminergic genes, DRD2 and DAT, in multigenerational families exposed to the Spitak earthquake.

Bailey JN, Goenjian AK, Noble EP, Walling DP, Ritchie T, Goenjian HA.  
*Psychiatry Res.* 2010 Aug 15;178(3):507-10. doi: 10.1016/j.psychres.2010.04.043.

Depression and PTSD symptoms among bereaved adolescents 6(1/2) years after the 1988 Spitak earthquake.

Goenjian AK, Walling D, Steinberg AM, Roussos A, Goenjian HA, Pynoos RS.  
*J Affect Disord.* 2009 Jan;112(1-3):81-4. doi: 10.1016/j.jad.2008.04.006. Epub 2008 Jun 10.

Heritabilities of symptoms of posttraumatic stress disorder, anxiety, and depression in earthquake exposed Armenian families.

Goenjian AK, Noble EP, Walling DP, Goenjian HA, Karayan IS, Ritchie T, Bailey JN.  
*Psychiatr Genet.* 2008 Dec;18(6):261-6. doi: 10.1097/YPG.0b013e3283060f48.

Posttraumatic stress and depressive reactions among Nicaraguan adolescents after hurricane Mitch.

Goenjian AK, Molina L, Steinberg AM, Fairbanks LA, Alvarez ML, Goenjian HA, Pynoos RS.  
*Am J Psychiatry.* 2001 May;158(5):788-94.

**LANGUAGES:**

English: Native Language

Armenian: speak fluently and read/ write with high proficiency

Spanish: speak, read, and write with basic competence